0000899243-23-001517.txt : 20230110 0000899243-23-001517.hdr.sgml : 20230110 20230110191248 ACCESSION NUMBER: 0000899243-23-001517 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230106 FILED AS OF DATE: 20230110 DATE AS OF CHANGE: 20230110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klee Justin B. CENTRAL INDEX KEY: 0001898314 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 23522285 MAIL ADDRESS: STREET 1: C/O AMYLYX PHARMACEUTICALS, INC. STREET 2: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-06 0 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001898314 Klee Justin B. C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 1 1 0 0 Co-Chief Executive Officer Common Stock 2023-01-06 4 S 0 4122 36.0789 A 2894463 D Common Stock 2023-01-06 4 S 0 1846 36.7888 A 2892617 D Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. /s/ Joshua B. Cohen, as Attorney in Fact 2023-01-10